Share ownership Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:26 14/05/2026 am IST			5-day change	1st Jan Change
113.45 ^USD	+0.96%		-0.10%	+7.78%

13/05	European shares lifted by miners and tech; Mideast in focus	RE
12/05	Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at Asco 2026	RE

Share class: Merck & Co., Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,57,72,34,558	2,46,82,07,522 ( 69 %)	1,10,74,10,143 ( 30.96 %)	69 %

Major shareholders: Merck & Co., Inc.

Name	Equities	%	Valuation
Vanguard Capital Management LLC 7.544 %	18,63,23,766	7.544 %	20 343 M $
Vanguard Capital Management LLC 6.518 %	16,09,87,624	6.518 %	17 577 M $
BlackRock Advisors LLC 6.516 %	16,09,33,559	6.516 %	17 571 M $
STATE STREET CORPORATION 4.86 %	12,00,40,168	4.86 %	13 106 M $
Wellington Trust Co., NA 3.5 %	8,64,35,458	3.5 %	9 437 M $
Vanguard Portfolio Management LLC 2.725 %	6,73,04,305	2.725 %	7 348 M $
Geode Capital Management LLC 2.431 %	6,00,47,984	2.431 %	6 556 M $
BlackRock Life Ltd. 2.083 %	5,14,36,428	2.083 %	5 616 M $
Eaton Vance Management 1.82 %	4,49,46,021	1.82 %	4 907 M $
Fidelity Management & Research Co. LLC 1.651 %	4,07,67,953	1.651 %	4 451 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Caixa DTVM SA 0.001001 %	1,97,850	0.001001 %	3 M $
Safra Asset CTVM SA (Investment Management) 0.000268 %	53,000	0.000268 %	726 644 $
XP Allocation Asset Management Ltda. 0.000026 %	5,196	0.000026 %	71 239 $

Breakdown by shareholder type

Institutional	69.46%
Other	8.43%
State Street Corp.	4.86%
Schweizerische Nationalbank	0.29%
Swedbank AB	0.29%
Sumitomo Mitsui Trust Group, Inc.	0.25%
Governments	0.16%
SEI Investments Co.	0.11%
The Bank of Nova Scotia	0.08%
Danske Bank A/S	0.07%
Manulife Financial Corp.	0.07%
Fifth Third Bancorp	0.06%
Regions Financial Corp.	0.05%
Individuals	0.05%
Münchener Rückversicherungs-Gesellschaft AG	0.03%
First Financial Bankshares, Inc.	0.03%
Old Republic International Corp.	0.03%
ING Groep NV	0.03%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Zurich Insurance Group AG	0.02%
Peapack-Gladstone Financial Corp.	0.02%
Commerzbank AG	0.01%
Banque Cantonale Vaudoise	0.01%
First Horizon Corp. (Tennessee)	0.01%
Fairfax Financial Holdings Ltd.	0.01%
ABN AMRO Bank NV	0.01%
Rathbones Group Plc	0.01%
The Allstate Corp.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Cullen/Frost Bankers, Inc.	0.01%
Hancock Whitney Corp.	0.01%
Unknown	15.48%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	64.78%
United Kingdom	7.77%
Canada	2.41%
Norway	1.74%
Sweden	1.06%
France	0.95%
Australia	0.89%
Japan	0.78%
Switzerland	0.78%
Denmark	0.67%
Germany	0.51%
Netherlands	0.33%
Hong Kong	0.32%
South Korea	0.31%
Italy	0.19%
Ireland	0.17%
Belgium	0.14%
Luxembourg	0.13%
Spain	0.09%
Malaysia	0.08%
Finland	0.08%
New Zealand	0.07%
Individuals	0.05%
Singapore	0.05%
Czech Republic	0.03%
Austria	0.03%
Russia	0.02%
Puerto Rico	0.01%
China	0.01%
South Africa	0.01%
Saudi Arabia	0.01%
Slovenia	0.01%
Brazil	0.01%
Taiwan	0.01%
Liechtenstein	0.01%

Based on 1000 largest holdings

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

15/05 -

More about the company